Floatz logo

otx015

Multiple Myeloma

Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 1Dormant
D
29/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
19/ 100
Competitive Position
59/ 100

Competitive context

498 Active assets in the Multiple Myeloma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

otx015 is also rated in:

glioblastomaDormant
C
Indicative ·
38 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
35 / 100
View asset →
diffuse large B-cell lymphomaDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →